Navigation Links
Clinical Immunology Society Appoints Vincent Bonagura, MD as Editor-in-Chief of the Journal of Clinical Immunology
Date:3/11/2013

Milwaukee, WI (PRWEB) March 11, 2013

The Clinical Immunology Society (CIS) is pleased to announce that Dr. Vincent Bonagura has been selected to serve as the new Editor-in-Chief of the Journal of Clinical Immunology (JoCI) for a five-year term beginning February 1, 2013. Dr. Bonagura is the Chief of the Division of Allergy and Immunology and the Jack Hausman Professor of Pediatrics at the Alexandra and Steven Cohen Children's Medical Center of the North Shore-Long Island Jewish Health System in New York, where he also directs the Jeffrey Modell Foundation Diagnostic Center and the Laboratory of Host Defense. He is also Professor of Molecular Medicine at the Feinstein Institute for Medical Research at North Shore - Long Island Jewish Health System. His research interests include virus infections, autoimmunity and primary immune deficiency; and editorial experience has been with the Annals of Allergy and Immunology, Clinical and Diagnostic Laboratory Immunology, and Clinical Immunology.

"We're very excited to have Dr. Bonagura involved with the journal and I'm certain that under his leadership, we will continue to advance the visibility and reputation of the JoCI and CIS," said CIS President, Lawrence B. Schwartz, MD PhD.

In addition, Dr. Jean-Laurent Casanova has accepted the position of Deputy Editor. Jean-Laurent Casanova, MD PhD received his medical degree from the Université Paris Descartes in 1987. After receiving training at the Pasteur Institute in Paris and the Ludwig Institute for Cancer Research in Lausanne, Switzerland, he received his PhD in immunology from the Université Pierre et Marie Curie in 1992. Following a residency in pediatrics, he completed a clinical fellowship in the pediatric immunology-hematology unit of the Necker Medical School in Paris. In 1999, he was appointed a professor of pediatrics at Necker, where, with Dr Laurent Abel, he cofounded and co-directe
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. An Evaluation of Clinical Trial Quality in Russia and Ukraine, new webinar hosted by Xtalks
2. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
3. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
4. PhUSE Announces Open Source Repository of Clinical Trial Informatics Analysis Code
5. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
6. NeoClinical Launches Neo PayPerPatient Clinical Trial Recruitment
7. Eastern Clinical Trials Russia CRO Passes EMA Inspection
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
10. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
11. Cutting the Cost of Clinical Research: The Solution Comes from Russia, New Xtalks Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... NORWALK, Conn. , March 5, 2015 /PRNewswire/ ... Network , a leading online community to ... understanding of the newest information available regarding the ... coverage of kidney cancer. March is ... there are very few effective adjuvant treatment options ...
(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... Oct. 5 ISTO Technologies, Inc. (ISTO), an  orthobiologics ... today the completion of patient enrollment in the Phase ... formulation of juvenile chondrocytes designed for the treatment of ... at two clinical sites. All patients enrolled in the ...
... the many pressing concerns of the day, fear of plague ... for those whose responsibility it is to combat bioterrorism, plague ... include scientists like medical researcher Steve Smiley, whose lab at ... will protect the public against weaponized forms of plague. The ...
... AMGN ) today announced that results from ... evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or ... colorectal cancer (mCRC), respectively, were published online in the ... "Both studies demonstrated that Vectibix administered with chemotherapy significantly ...
Cached Biology Technology:ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... A new unique work published by Springer, the ... the influence of complexity and system science to a ... In eleven volumes, available in print and electronically, ... applying the concepts of complexity theory together with the ...
... compounds, in addition to sulfate, may play an important ... carbonates in the Earth,s oceans, according to a team ... may have been key to methane reduction in the ... used to believe that microbes only consumed methane in ...
... for Cancer Research applauds President Obama,s nomination of Francis ... of the National Institutes of Health (NIH). ... said Tyler Jacks, Ph.D., president of the American Association ... Genome Research Institute and the Human Genome Project has ...
Cached Biology News:A complete view of complexity in science and society in a new authoritative reference work 2Methane-eating microbes can use iron and manganese oxides to 'breathe' 2
...
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... 9(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 9(S)-HODE is produced by the lipoxygenation of ... has been detected in atherosclerotic plaques, as an ...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: